Benzinga | Jul 20, 2020 09:32AM EDT

Canaccord Genuity Initiates Coverage On Amryt Pharma with Buy Rating, Announces Price Target of $40

Canaccord Genuity analyst Michelle Gilson initiates coverage on Amryt Pharma (NASDAQ:AMYT) with a Buy rating and announces Price Target of $40.